// App-Quantinova.ai

: FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).

Researchers

Presenter

  • Paul L. Nguyen

Principal Investigators

  • Dana E. Rathkopf

  • Karen E. Hoffman

  • Amado J. Zurita

  • Daniel Eidelberg Spratt

  • Robert Timothy Dess

  • Stanley L. Liauw

  • Russell Zelig Szmulewitz

  • David Johnson Einstein

  • Glenn Bubley

  • James B. Yu

  • Yi An

  • Anthony C. Wong

  • Felix Y Feng

  • Rana R. McKay

  • Brent S. Rose

  • Kee-Young Shin

  • Adam S. Kibel

  • Mary-Ellen Taplin

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • UCSF, San Francisco, CA

  • University of California, San Francisco, San Francisco, CA

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA

  • Michigan Medicine, Ann Arbor, MI

  • Yale New Haven Hospital, New Haven, CT

  • New York Presbyterian - Columbia, New York, NY

  • University Hospitals Cleveland Medical Center / Case Western Reserve University School of Medicine, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Bicalutamide

  • Prednisone

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03141671

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved